Intelligent Bio Solutions posts Exhibit 4.1 Amended Series H-1 Warrant

Rhea-AI Filing Summary

INTELLIGENT BIO SOLUTIONS, INC. (INBS) filed an Form 8-K reporting a material event that attaches the Form of Amended Series H-1 Warrant as an exhibit. The filing lists Exhibit 4.1 as the amended warrant form and includes an Inline XBRL cover page data file. The document is signed by Spiro Sakiris, Chief Financial Officer.

The filing notifies stakeholders that the company has documented changes to the Series H-1 warrant in a formal amended warrant agreement, but it does not disclose the economic terms, number of warrants affected, exercise price, expiration, or any related cash or equity effects.

Positive

• Amended warrant form disclosed via Exhibit 4.1, increasing contractual transparency
• Signed by CFO, indicating formal company authorization and completion of the filing process

Negative

• No economic terms disclosed (exercise price, quantity, expiration) so investor impact is unclear
• No explanation of effect on capitalization table or potential dilution is provided

Insights

Securities Filings Analyst

TL;DR: An amended warrant form was filed, improving disclosure but lacking economic detail.

The filing attaches the Form of Amended Series H-1 Warrant, which is a legal document that defines rights tied to the company's warrants. Making the amended form public clarifies the contractual terms that will govern holder rights going forward.

The document on its face does not state key economic variables such as the exercise price, quantity, or expiration, so investors cannot gauge dilution or cash‑inflow impact from this filing alone. Watch for subsequent filings or exhibits that specify numeric terms or related agreements within the next reporting cycle.

Corporate Governance Specialist

TL;DR: Signature by the CFO confirms formal corporate action but material impact remains unclear.

The 8-K includes a formal signature by the Chief Financial Officer, indicating the company completed an internal approval step and has presented the amended warrant form for public record. Publishing the instrument supports transparency about the company’s capital structure instruments.

Because the filing does not include transaction amounts or board minutes, its governance implications are limited; stakeholders should expect further information if the amendment changes holder rights materially or precedes an issuance or amendment that affects equity ownership.

false 0001725430 0001725430 2025-09-20 2025-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 20, 2025

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39825		82-1512711
(State of Incorporation)		(Commission File Number)		(IRS employer identification no.)

135 West, 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 828-8258

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 20, 2025, the Board of Directors of Intelligent Bio Solutions Inc. (the “Company”) approved extending the termination date of the Company’s outstanding Series H-1 Common Stock Purchase Warrants (the “Series H-1 Warrants”) from 5:00 p.m. (New York City time) on September 27, 2025, to 5:00 p.m. (New York City time) on March 27, 2026. The exercise prices and other terms of the Series H-1 Warrants remain unchanged. There are currently outstanding Series H-1 Warrants to purchase an aggregate of 1,034,213 shares of the Company’s common stock held by six warrant holders, each of whom consented to extending the termination date. The Company did not receive any consideration in connection with extending the termination date of the Series H-1 Warrants. Other than the consent of the warrant holders to the extension, there are no agreements or understandings between the Company and the warrant holders related to extending the termination date of the Series H-1 Warrants.

The foregoing description of the amended Series H-1 Warrants is qualified in its entirety by reference to the full text of the Series H-1 Warrant, a copy of which is attached to this Current Report on Form 8-K as Exhibit 4.1.

Item 9.01 Financial Statements and Exhibits.

No.		Description
4.1		Form of Amended Series H-1 Warrant.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	September 25, 2025
		INTELLIGENT BIO SOLUTIONS INC.
		By:	/s/ Spiro Sakiris
		Name:	Spiro Sakiris
		Title:	Chief Financial Officer

FAQ

What did INBS file on the 8-K?

The company filed an 8-K attaching the Form of Amended Series H-1 Warrant as Exhibit 4.1 and included an Inline XBRL cover page; the filing is signed by CFO Spiro Sakiris.

Does the filing state the exercise price or number of Series H-1 warrants?

No. The 8-K lists the amended warrant form but does not disclose the exercise price, number of warrants, or expiration.

Is there information on how the amendment affects INBS's capitalization?

No. The filing does not quantify dilution, cash proceeds, or changes to the capitalization table.

Who signed the 8-K for INBS?

The form is signed by Spiro Sakiris, the company’s Chief Financial Officer.

What should investors expect next after this filing?

Expect follow‑up disclosures if numeric terms or related issuances are adopted; the 8-K itself contains no timing or numeric milestones.